newsfilter
← Latest News
GlobeNewswire·

Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Presented robust CRB-701 clinical data at ESMO 2025 - 3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 HNSCC registrational study planned to start mid-2026Completed $75